[The French pharmacovigilance system: structure and missions]

Area of Science:

• Pharmacovigilance and Pharmacoepidemiology
• Drug Safety and Adverse Event Monitoring
• Public Health and Regulatory Science

Background:

• The French pharmacovigilance system utilizes a decentralized network of 31 regional centers.
• Effective pharmacovigilance relies on robust causality assessment methods.
• Pharmacoepidemiology enhances the evaluation of drug-related adverse effects.

Purpose of the Study:

• To describe the structure and function of the French pharmacovigilance system.
• To outline the compulsory causality assessment methods employed.
• To highlight the role of the National Commission of Pharmacovigilance in drug safety.

Main Methods:

• Network of 31 regional pharmacovigilance centers.
• Compulsory causality assessment for adverse drug reactions.
• Application of pharmacoepidemiology for enhanced evaluation.
• Centralized data assessment by the National Commission of Pharmacovigilance at AFSSAPS.

Main Results:

• A comprehensive network ensures proximity to healthcare professionals.
• Standardized causality assessment ensures rigorous evaluation of drug-adverse effect relationships.
• Pharmacoepidemiology provides additional data for robust assessment.
• AFSSAPS centralizes data for informed decision-making.

Conclusions:

• The French pharmacovigilance system integrates a network, standardized assessment, and pharmacoepidemiology for drug safety.
• The National Commission provides expert advice to authorities for preventing adverse drug effects.
• This system aims to minimize drug-related harm through continuous monitoring and evaluation.